Showing 2401-2410 of 5794 results for "".
- In Review: VCS Virtual Format Hailed as a Successhttps://practicaldermatology.com/news/in-review-vcs-virtual-format-hailed-a-success/2460601/After a decade and a half of bringing topline aesthetic education to Las Vegas, VCS went virtual this fall. “While it wasn't live—it was virtual—I knew it was absolutely fantastic,” says meeting
- New from Lutronic: Accufit for Muscle Stimulationhttps://practicaldermatology.com/news/new-from-lutronic-accufit-for-muscle-stimulation/2460599/Lutronic is launching Accufit, a new device for targeted muscle activation. Eight IntelliSTIM electrodes distribute energy and generate strong muscular contractions on any area needed to be treated without pain or skin sensitivity. Accufit's IntelliPhase waveforms produce four
- Dermatologist Named AAD Patient Hero for Saving South Florida Man’s Life with Early Diagnosis of Lung Cancerhttps://practicaldermatology.com/news/dermatologist-named-aad-patient-hero-for-saving-south-florida-mans-life-with-early-diagnosis-of-lung-cancer/2460583/Brittany Smirnov, DO is an American Academy of Dermatology Patient Care Hero for her role in diagnosing and treating a patient with stage IV metastatic lung cancer. When South Florida resident Richard Danzer developed a cyst on his back that grew larger and more painful over t
- FDA Grants Priority Review for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe ADhttps://practicaldermatology.com/news/fda-grants-priority-review-for-pfizers-abrocitinib-an-oral-once-daily-jak1-inhibitor-for-patients-12-and-up-with-moderate-to-severe-ad/2460580/The U.S. Food and Drug Administration (FDA) has granted Priority Review designation to Pfizer’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in
- Soligenix's Phase 3 FLASH Study Continues to Demonstrate Positive Benefits of SGX301 in Cutaneous T-Cell Lymphoma Patientshttps://practicaldermatology.com/news/soligenixs-phase-3-flash-study-continues-to-demonstrate-positive-benefits-of-sgx301-in-cutaneous-t-cell-lymphoma-patients/2460576/Continued optional treatment with Soligenix, Inc.’s SGX301 (synthetic hypericin) demonstrates positive benefits in patients with cutaneous T-Cell lymphoma Nearly half of all patients in Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial conti
- Label Update for Enstilar Foam Highlights Long-Term Use in Adultshttps://practicaldermatology.com/news/label-update-for-enstilar-foam-highlights-long-term-use-in-adults/2460575/The US Prescribing Information (USPI) for Enstilar® (calcipotriene and betamethasone dipropionate) Foam from LEO Pharma A/S now includes data on long-term use in adults with plaque psoriasis. The update results from the FDA approving a supplemental New Drug Application (sNDA).
- Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Patients with Moderate-to-Severe AD at EADV Virtual Meetinghttps://practicaldermatology.com/news/connect-biopharma-to-present-additional-positive-results-from-the-phase-1b-study-of-cbp-201-for-patients-with-moderate-to-severe-ad-at-eadv-virtual-meeting/2460574/Connect Biopharma is slated to present the full results from the Phase 1b study of CPB-201, a novel IL-4R&alpha
- Industry Responds to COVID-19: TrueHero Face Shieldshttps://practicaldermatology.com/news/truehero-face-shields-offer-reusable-medical-grade-protection/2460572/Responding to the need for PPE across the US, Jamestown Plastics, has pivoted production to manufacture face shields to protect from COVID-19. The TrueHero Extreme Coverage Shield is suitable for medical use, including in dermatology and aesthetic practices.
- New from BTL: Emsculpt NEO Launcheshttps://practicaldermatology.com/news/new-from-btl-emsculpt-neo-launches/2460571/The first procedure to combine radio frequency heating and high-intensity focused electromagnetic waves into a single therapy, Emsculpt NEO from BTL, has launched. It is FDA-cleared to eliminate fat cells non-invasively. Emsc
- DermOQ To Buy Skin Products's ECHO2 Plus Oxygen Facial Treatment Product Linehttps://practicaldermatology.com/news/dermoq-to-buy-skin-products-incs-echo2-plus-oxygen-facial-treatment-product-line/2460569/DermOQ Inc. is purchasing Skin Products Inc.’s ECHO2 Plus and Oxyceuticals oxygen facial treatment product lines. DermOQ offers its topical oxygen products under the brand names DermOQ Oxygen Lab and